Long‐term real‐life adherence of percutaneous tibial nerve stimulation in over 400 patients

Dorsthorst, Manon J. te; Heesakkers, John; Balken, Michael R. van

doi:10.1002/nau.24254

Cited by 29 publications

(23 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PTNM therefore remains a well-tolerated and efficacious option for the treatment of OAB. Despite this, there remains a high drop-out rate, with retrospective data indicating an over 40% discontinuation rate [72], similar to the drop-out rates reported with BTX. Only 40% to 60% of patients receive a second injection, with subsequent treatments decreasing even further [73][74][75].…”

Section: Percutaneous Tibial Nerve Modulationsupporting

confidence: 56%

Overactive Bladder: Where We Are and Where We Are Going

Mohan¹,

Lee²,

Kobashi³

2021

Société Internationale D’Urologie Journal

View full text Add to dashboard Cite

Overactive bladder (OAB) is a heterogeneous syndrome estimated to affect approximately 10% to 15% of men and women globally. OAB not only negatively impacts quality of life but also results in a significant financial burden to both patients and health systems. Therefore, it is crucial that OAB is properly addressed. This manuscript provides a general review of the diagnostic algorithm for OAB and treatment per the AUA/SUFU guidelines, and an overview of new developments in OAB therapy. Given the wide array of therapeutic options that currently exist and those that are currently under development, there is tremendous opportunity to treat OAB successfully and positively affect our patients’ lives.

show abstract

Section: Percutaneous Tibial Nerve Modulationsupporting

confidence: 56%

Overactive Bladder: Where We Are and Where We Are Going

Mohan¹,

Lee²,

Kobashi³

2021

Société Internationale D’Urologie Journal

View full text Add to dashboard Cite

show abstract

“…For the most part, OAB patients stop these forms of therapy because of side effects or a lack of efficacy in the longerterm. 11,14 In our view, this is also the case for TTNS in the real-life setting. The limitations of our study are the number of patients which were included and the single center nature of the study.…”

Section: Discussionmentioning

confidence: 76%

“…In real-life PTNS studies ( n = 183) the median follow up of patients during maintenance treatment is 18 months. 11 Sirls et al 12 describe in their real-world study that 55% of their patients continued maintenance PTNS treatment after 3 months. However, the reasons for discontinuation of PTNS differ from TTNS, mainly because of the logistic intensity (frequent clinical visits) of the PTNS treatment compared to TTNS.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Real-life patient experiences of TTNS in the treatment of overactive bladder syndrome

Dorsthorst

Balken

Janssen

et al. 2021

Therapeutic Advances in Urology

Self Cite

View full text Add to dashboard Cite

Introduction and objectives: Overactive bladder syndrome (OAB) is defined as urinary urgency, with or without urgent urinary incontinence; it is often associated with urinary frequency and nocturia, in the absence of any pathological or metabolic conditions that may cause or mimic OAB. The aim of this study was to evaluate the long-term real-life adherence of transcutaneous tibial nerve stimulation (TTNS) in the treatment of OAB, patient satisfaction of the treatment, and reasons for quitting therapy. Materials and methods: In this single center study, all patients who had a positive effect on percutaneous tibial nerve stimulation (PTNS) and continued to receive home-based treatment with TTNS since 2012 were included for analysis. Patients were retrospectively asked to fill out a questionnaire regarding satisfaction, reasons for quitting, and additional or next line of therapy. Results: We included 42 patients for this study, 81% of these patients were female ( n = 34). The median age was 67 years (range 36–86). Most of the patients (64%, n = 27) were diagnosed with OAB wet. The median TTNS treatment persistence was 16 months (range 1–112 months). Reasons and percentages for stopping therapy were: 55% stopped treatment due to loss of effect, and 24% stopped because of preferring other type of neuromodulation. The mean satisfaction score (scale 1–10) in patients who continued TTNS was 6.2 ( n = 9, SD 1.30) versus 5.4 ( n = 29, SD 2.24) for patients who quit therapy. We did not find a statistically significant difference between the two groups ( p = 0.174). Conclusion: TTNS, although effective in the short-term, is not effective in the long-term. In combination with a low satisfaction rate among patients, there is a need for improvement in terms of OAB treatment modalities.

show abstract

“…Furthermore, the included studies did not investigate long-term effects and whether lifelong maintenance therapy is required. Therefore, we speculate, based on studies investigating PTNS in patients with OAB, that maintenance therapy is required for a sustained response in the long term [31].…”

Section: Discussionmentioning

confidence: 99%

Transcutaneous Electrical Nerve Stimulation and Percutaneous Tibial Nerve Stimulation to Treat Idiopathic Nonobstructive Urinary Retention: A Systematic Review

Coolen

Groen

Scheepe

et al. 2021

European Urology Focus

View full text Add to dashboard Cite

Context: Transcutaneous electrical nerve stimulation (TENS) and percutaneous tibial nerve stimulation (PTNS) provide minimally invasive ways to treat idiopathic nonobstructive urinary retention (NOUR). Objective: To assess the efficacy of TENS and PTNS for treating idiopathic NOUR. Evidence acquisition: A systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement. Embase, Medline, Web of Science Core Collection, and the Cochrane CENTRAL register of trials were searched for all relevant publications until April 2020. Evidence synthesis: A total of 3307 records were screened based on the title and abstract. Eight studies met the inclusion criteria and none of the exclusion criteria. Five studies, all from the same group, reported the efficacy of PTNS and two that of TENS in adults with idiopathic NOUR. One study reported the efficacy of TENS in children with idiopathic NOUR. Objective success was defined as a 50% decrease in the number of catheterizations per 24 h or in the total catheterized volume in 24 h. The objective success rate of PTNS ranged from 25% to 41%. Subjective success was defined as the patient's request for continued chronic treatment with PTNS, and ranged from 46.7% to 59%. Eighty percent of women who underwent transvaginal stimulation reported an improvement such as a stronger stream when voiding. TENS in children reduced postvoid residual and urinary tract infections. Conclusions: The efficacy of TENS and PTNS in the treatment of idiopathic NOUR is limited and should be verified in larger randomized studies before application in clinical practice. Patient summary: The outcomes of transcutaneous electrical nerve stimulation and percutaneous tibial nerve stimulation for the treatment of urinary retention of unknown origin were reviewed. Whether these treatments are superior to other treatments could not be established.

show abstract

Long‐term real‐life adherence of percutaneous tibial nerve stimulation in over 400 patients

Cited by 29 publications

References 30 publications

Overactive Bladder: Where We Are and Where We Are Going

Overactive Bladder: Where We Are and Where We Are Going

Real-life patient experiences of TTNS in the treatment of overactive bladder syndrome

Transcutaneous Electrical Nerve Stimulation and Percutaneous Tibial Nerve Stimulation to Treat Idiopathic Nonobstructive Urinary Retention: A Systematic Review

Contact Info

Product

Resources

About